53 related articles for article (PubMed ID: 37307526)
1. Discovery and Structure-Based Design of Inhibitors of the WD Repeat-Containing Protein 5 (WDR5)-MYC Interaction.
Ding J; Liu L; Chiang YL; Zhao M; Liu H; Yang F; Shen L; Lin Y; Deng H; Gao J; Sage DR; West L; Llamas LA; Hao X; Kawatkar S; Li E; Jain RK; Tallarico JA; Canham SM; Wang H
J Med Chem; 2023 Jun; 66(12):8310-8323. PubMed ID: 37307526
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core.
Tian J; Teuscher KB; Aho ER; Alvarado JR; Mills JJ; Meyers KM; Gogliotti RD; Han C; Macdonald JD; Sai J; Shaw JG; Sensintaffar JL; Zhao B; Rietz TA; Thomas LR; Payne WG; Moore WJ; Stott GM; Kondo J; Inoue M; Coffey RJ; Tansey WP; Stauffer SR; Lee T; Fesik SW
J Med Chem; 2020 Jan; 63(2):656-675. PubMed ID: 31858797
[TBL] [Abstract][Full Text] [Related]
3. Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models.
Teuscher KB; Chowdhury S; Meyers KM; Tian J; Sai J; Van Meveren M; South TM; Sensintaffar JL; Rietz TA; Goswami S; Wang J; Grieb BC; Lorey SL; Howard GC; Liu Q; Moore WJ; Stott GM; Tansey WP; Lee T; Fesik SW
Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2211297120. PubMed ID: 36574664
[TBL] [Abstract][Full Text] [Related]
4. Discovery, evaluation and mechanism study of WDR5-targeted small molecular inhibitors for neuroblastoma.
Han QL; Zhang XL; Ren PX; Mei LH; Lin WH; Wang L; Cao Y; Li K; Bai F
Acta Pharmacol Sin; 2023 Apr; 44(4):877-887. PubMed ID: 36207403
[TBL] [Abstract][Full Text] [Related]
5. Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5-MYC Protein-Protein Interaction.
Macdonald JD; Chacón Simon S; Han C; Wang F; Shaw JG; Howes JE; Sai J; Yuh JP; Camper D; Alicie BM; Alvarado J; Nikhar S; Payne W; Aho ER; Bauer JA; Zhao B; Phan J; Thomas LR; Rossanese OW; Tansey WP; Waterson AG; Stauffer SR; Fesik SW
J Med Chem; 2019 Dec; 62(24):11232-11259. PubMed ID: 31724864
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-Based Optimization.
Teuscher KB; Meyers KM; Wei Q; Mills JJ; Tian J; Alvarado J; Sai J; Van Meveren M; South TM; Rietz TA; Zhao B; Moore WJ; Stott GM; Tansey WP; Lee T; Fesik SW
J Med Chem; 2022 Apr; 65(8):6287-6312. PubMed ID: 35436124
[TBL] [Abstract][Full Text] [Related]
7. Structure-Based Discovery of Potent, Orally Bioavailable Benzoxazepinone-Based WD Repeat Domain 5 Inhibitors.
Teuscher KB; Mills JJ; Tian J; Han C; Meyers KM; Sai J; South TM; Crow MM; Van Meveren M; Sensintaffar JL; Zhao B; Amporndanai K; Moore WJ; Stott GM; Tansey WP; Lee T; Fesik SW
J Med Chem; 2023 Dec; 66(24):16783-16806. PubMed ID: 38085679
[TBL] [Abstract][Full Text] [Related]
8. Mitotic gene regulation by the N-MYC-WDR5-PDPK1 nexus.
Streeter SA; Williams AG; Evans JR; Wang J; Guarnaccia AD; Florian AC; Al-Tobasei R; Liu Q; Tansey WP; Weissmiller AM
BMC Genomics; 2024 Apr; 25(1):360. PubMed ID: 38605297
[TBL] [Abstract][Full Text] [Related]
9. WDR5 facilitates recruitment of N-MYC to conserved WDR5 gene targets in neuroblastoma cell lines.
Bumpous LA; Moe KC; Wang J; Carver LA; Williams AG; Romer AS; Scobee JD; Maxwell JN; Jones CA; Chung DH; Tansey WP; Liu Q; Weissmiller AM
Oncogenesis; 2023 Jun; 12(1):32. PubMed ID: 37336886
[TBL] [Abstract][Full Text] [Related]
10. WIN site inhibition disrupts a subset of WDR5 function.
Siladi AJ; Wang J; Florian AC; Thomas LR; Creighton JH; Matlock BK; Flaherty DK; Lorey SL; Howard GC; Fesik SW; Weissmiller AM; Liu Q; Tansey WP
Sci Rep; 2022 Feb; 12(1):1848. PubMed ID: 35115608
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Potent 2-Aryl-6,7-dihydro-5 H-pyrrolo[1,2- a]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design.
Wang F; Jeon KO; Salovich JM; Macdonald JD; Alvarado J; Gogliotti RD; Phan J; Olejniczak ET; Sun Q; Wang S; Camper D; Yuh JP; Shaw JG; Sai J; Rossanese OW; Tansey WP; Stauffer SR; Fesik SW
J Med Chem; 2018 Jul; 61(13):5623-5642. PubMed ID: 29889518
[TBL] [Abstract][Full Text] [Related]
12. WDR5 is a conserved regulator of protein synthesis gene expression.
Bryan AF; Wang J; Howard GC; Guarnaccia AD; Woodley CM; Aho ER; Rellinger EJ; Matlock BK; Flaherty DK; Lorey SL; Chung DH; Fesik SW; Liu Q; Weissmiller AM; Tansey WP
Nucleic Acids Res; 2020 Apr; 48(6):2924-2941. PubMed ID: 31996893
[TBL] [Abstract][Full Text] [Related]
13. Exploring promising natural compounds for breast cancer treatment:
Nagar A; Dubey A; Sharma A; Singh M
J Biomol Struct Dyn; 2024 Feb; ():1-15. PubMed ID: 38356140
[TBL] [Abstract][Full Text] [Related]
14. Overlapping characteristics of weak interactions of two transcriptional regulators with WDR5.
Ahmad M; Imran A; Movileanu L
Int J Biol Macromol; 2024 Feb; 258(Pt 2):128969. PubMed ID: 38158065
[TBL] [Abstract][Full Text] [Related]
15. Phage-Display Based Discovery and Characterization of Peptide Ligands against WDR5.
Cao J; Fan T; Li Y; Du Z; Chen L; Wang Y; Wang X; Shen J; Huang X; Xiong B; Cao D
Molecules; 2021 Feb; 26(5):. PubMed ID: 33668971
[TBL] [Abstract][Full Text] [Related]
16. Small molecule WDR5 inhibitors down-regulate lncRNA expression.
Chang JY; Neugebauer C; Mues Genannt Koers A; 't Hart P
RSC Med Chem; 2024 Feb; 15(2):636-640. PubMed ID: 38389889
[TBL] [Abstract][Full Text] [Related]
17. Unannotated microprotein EMBOW regulates the interactome and chromatin and mitotic functions of WDR5.
Chen Y; Su H; Zhao J; Na Z; Jiang K; Bacchiocchi A; Loh KH; Halaban R; Wang Z; Cao X; Slavoff SA
Cell Rep; 2023 Sep; 42(9):113145. PubMed ID: 37725512
[TBL] [Abstract][Full Text] [Related]
18. Screening and optimization of phage display cyclic peptides against the WDR5 WBM site.
Song L; Cao J; Chen L; Du Z; Zhang N; Cao D; Xiong B
RSC Med Chem; 2023 Oct; 14(10):2048-2057. PubMed ID: 37859722
[TBL] [Abstract][Full Text] [Related]
19. WD Repeat Domain 5 Inhibitors for Cancer Therapy: Not What You Think.
Weissmiller AM; Fesik SW; Tansey WP
J Clin Med; 2024 Jan; 13(1):. PubMed ID: 38202281
[TBL] [Abstract][Full Text] [Related]
20. WD40 repeat domain proteins: a novel target class?
Schapira M; Tyers M; Torrent M; Arrowsmith CH
Nat Rev Drug Discov; 2017 Nov; 16(11):773-786. PubMed ID: 29026209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
